Skip to main content
. Author manuscript; available in PMC: 2012 Nov 9.
Published in final edited form as: J Am Chem Soc. 2011 Oct 17;133(44):17528–17531. doi: 10.1021/ja204301g

Figure 2.

Figure 2

Target-selective QD-SERT labeling via IDT318. (A) The structure of IDT318 ligand used in the study (see text for details of each component) (B) Column 1: Incubation of hSERT oocyte with 1 μM IDT318 ligand prior to 2.5 nM SA-QD treatment. The observed QD fluorescence forms a sharp halo correlating to the membrane of hSERT expressing oocyte. Column 2: Control experiment where the buffer-injected oocyte was treated under the same conditions as in column 1. Column 3: hSERT expressing oocyte was incubated with paroxetine (1 μM), subsequently exposed to the ligand/paroxetine mixture (1 μM/1 μM) prior to 2.5 nM SA-QD treatment. Column 4: hSERT expressing oocyte was pre-incubated with 5-HT (1 mM), subsequently exposed to the ligand/5-HT mixture (1 μM/mM) prior to 2.5 nM SA-QD treatment. The halo was dimmer but not completely blocked, indicating a competitive binding mechanism. Upper panel: DIC image; Lower panel: fluorescent image. Scale bar = 0.5 mm. The results are representative micrographs from at least 3 independent experiments.